ASH Clinical News December 2015 | Page 43
DLBCL is an aggressive disease2
Remarkably, more than half of patients are able to survive diffuse large B-cell
lymphoma (DLBCL) for 5 years or longer.1,3
Although strides have been made in the science of DLBCL,
we are determined to further our knowledge of this
aggressive disease
To learn more, visit BCellResearch.com
References: 1. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2012. National Cancer
Institute website. http://seer.cancer.gov/csr/1975_2012/results_single/sect_19_table.29_2pgs.pdf. Updated April 23, 2015.
Accessed June 15, 2015. 2. Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SH. Introduction and overview of the
classification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008:158-166.
3. Larouche J-F, Berger F, Chassagne-Clément C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell
lymphoma: clinical characteristics and outcome. J Clin Oncol. 2010;28(12):2094-2100.